Journal
ANNALS OF DIAGNOSTIC PATHOLOGY
Volume 18, Issue 4, Pages 214-219Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.anndiagpath.2014.03.006
Keywords
Leukemic mantle cell lymphoma; Non-nodal mantle cell lymphoma; Thp53 alteration; ATM deletion
Categories
Funding
- National Institutes of Health (NIH) [CA109335, CA122105]
- Dwoskin Family Foundation
- Redo Family Foundation
Ask authors/readers for more resources
Leukemic, non-nodal mantle cell lymphoma (MCL) is a relatively indolent disease characterized by asymptomatic leukemic presentation, non-nodal disease distribution, and slow disease progression, particularly in comparison to that of classic nodal MCL. We studied 3 cases of leukemic, non-nodal MCL in which TP53, ATM, and/or 13q14 deletions were identified. All three patients had disease progression leading to treatment requirements in two of the patients at 5 and 18 months after initial diagnosis. The third patient also clinically progressed 25 months after initial diagnosis but was lost to follow up despite recommendation for initiation of therapy. We present these cases as potential evidence that while leukemic non-nodal MCL is typically an indolent disease compared to classically defined mantle cell lymphoma, cytogenetic heterogeneity exists and cases with TP53, ATM, and/or 13q14 deletions may have a relatively aggressive clinical course. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available